MonTa Biosciences is developing MBS8, a lipid nanoparticle formulation that enhances tumor immune cell migration and promotes tumor cell destruction through a TLR7 agonist. This approach aims to improve cancer treatment outcomes by leveraging the immune system to establish a lasting immune memory against metastatic disease.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to generate a lasting immune response, leaving patients vulnerable to metastatic disease. Traditional approaches may not effectively stimulate the immune system within the tumor microenvironment, limiting their ability to eradicate cancer cells and prevent recurrence.
Solution
MonTa Biosciences is developing MBS8, a lipid nanoparticle (LNP) formulation designed to enhance tumor immune cell migration and promote tumor cell destruction through a TLR7 agonist. The LNP formulation increases the therapeutic index and reduces systemic cytokine production, resulting in a favorable safety profile. Administered via IV infusion, MBS8 incorporates a novel small molecule TLR7 NCE agonist, demonstrating superior anti-tumor activity in preclinical models compared to existing treatments. MBS8 exhibits synergy with immune checkpoint inhibitors, radiotherapy, and chemotherapy, achieving complete remission in preclinical models.
Target Audience
The primary target audience includes oncologists and patients seeking more effective cancer immunotherapies, as well as researchers and pharmaceutical companies focused on developing novel cancer treatments.
Features
- Lipid nanoparticle (LNP) formulation enhances targeted delivery of TLR7 agonist to the tumor microenvironment.
- TLR7 agonist stimulates immune cell migration and promotes tumor cell destruction.
- Engineered LNPs reduce systemic cytokine production, improving safety profile.
- IV infusion administration minimizes complications for doctors and patients.
- Demonstrates superior anti-tumor activity in preclinical models.
- Synergistic effects with immune checkpoint inhibitors, radiotherapy, and chemotherapy observed in preclinical models.